New diabetes drug shows promise in early trial
NCT ID NCT00497198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug, MCI-196, in 183 people with type 2 diabetes to see if it could help control blood sugar and improve cholesterol levels. Participants took the drug or a placebo for 12 weeks. The goal was to measure changes in blood glucose and HbA1c, a key diabetes marker, as well as safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?